San Francisco start-up BlackThorn aims to combine cloud- and AI-based data collection tool PathFinder with brain imaging technology and behavioural evaluation techniques in a "targeted, predictive approach" to finding suitable patients for clinical trials. The company is working on an AI system that can identify people who are at risk of developing Alzheimer's disease based on their behaviour patterns over time. It aims to increase the level of precision in establishing a drug's effectiveness.
San Francisco start-up BlackThorn aims to combine cloud- and AI-based data collection tool PathFinder with brain imaging technology and behavioural evaluation techniques in a "targeted, predictive approach" to finding suitable patients for clinical trials. Blackthorn recently raised $76m in a series B round to fund human trials of treatments for mood or anxiety disorders and autism. It aims to increase the level of precision in establishing a drug's effectiveness.